Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2019.0028
• Publication Date: 2019-06-17T18:24:08Z
• Authors: Martin S. Tallman; Eunice S. Wang; Jessica K. Altman; Frederick R. Appe...; Vijaya Raj Bhatt; Dale Bixby; Steven E. Coutre; Marcos De Lima; Amir T. Fathi; Melanie Fiorella; James M. Foran; Aric C. Hall; Meagan Jacoby; Jeffrey Lancet; Thomas W. LeBlanc; Gabriel Mannis; Guido Marcucci; Michael G. Martin; Alice Mims; Margaret R. O’Don...; Rebecca Olin; Deniz Peker; Alexander Perl; Daniel A. Pollyea; Keith Pratz; Thomas Prebet; Farhad Ravandi; Paul J. Shami; Richard M. Stone; Stephen A. Strick...; Matthew Wieduwilt; Kristina M. Gregory; ; Lydia Hammond; Ndiya Ogba
• Keywords: Histocompatibility Testing; Remission Induction; Age Factors; Hematopoietic Stem Cell Transplantation; Graft vs Host Disease; Middle Aged; Medical Oncology; Risk Assessment; Disease-Free Survival; United States; 3. Good health; Leukemia, Myeloid, Acute; 03 medical and health sciences; 0302 clinical medicine; HLA Antigens; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Biomarkers, Tumor; Humans; Transplantation, Homologous; Aged

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.